Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
– ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction –
Covered in this story
Call it yourself
No calls on $ASMB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Assembly Biosciences →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.